Who Paid My Doc
Nora Chan
Neurology East Meadow, NY Medical Doctor
NPI 1073774725 CMS profile 49277
1530 Front St Ste 400, East Meadow, NY 11554
General payments
$37,307
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$36,894
Through program year 2025, Nora Chan of East Meadow, NY is reported in the CMS Open Payments database as having received $37,307 across 95 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $36,894 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 88th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $378 | 14 | |
| 2024 | General | $25 | 1 | |
| 2023 | General | $1,586 | 7 | |
| 2020 | General | $11,307 | 15 | |
| 2019 | General | $24,011 | 58 |
Beside peers
- Nora Chan
- Neurology median
- Middle half of Neurology
- National median
In program year 2025, general payments to Nora Chan were reported at $378. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.
Show as a table
| Year | Nora Chan | Neurology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $24,011 | $474 | $118–$2,177 | $163 |
| 2020 | $11,307 | $367 | $82–$2,309 | $114 |
| 2021 | $0 | $438 | $104–$2,547 | $132 |
| 2022 | $0 | $442 | $103–$2,388 | $149 |
| 2023 | $1,586 | $464 | $119–$2,312 | $160 |
| 2024 | $25 | $468 | $119–$2,323 | $164 |
| 2025 | $378 | $457 | $118–$2,344 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 45 drugsPart D claims
3,005
Drug cost
$1,308,571
Branded share of claims
52.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Nuplazid Pimavanserin Tartrate | Brand | 51 | $354,658 | |
| Gocovri Amantadine Hcl | Brand | 46 | $192,158 | |
| Rytary Carbidopa/Levodopa | Brand | 87 | $172,573 | |
| Neupro Rotigotine | Brand | 70 | $109,664 | |
| Xadago Safinamide Mesylate | Brand | 49 | $104,063 | |
| Nourianz Istradefylline | Brand | 22 | $95,165 | |
| Ingrezza Valbenazine Tosylate | Brand | 12 | $93,640 | |
| Rasagiline Mesylate | Generic | 136 | $36,229 | |
| Carbidopa-Levodopa Carbidopa/Levodopa | Brand | 740 | $25,932 | |
| Nuedexta Dextromethorphan Hbr/Quinidine | Brand | 12 | $21,848 |
The 10 drugs with the highest cost, of 45 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 29 billing codesPaid by Medicare
$253,654
Medicare patients
653
Services billed
20,932
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 57% | |
| Ischemic heart disease | 36% | |
| Depression | 34% | |
| Diabetes | 30% | |
| Alzheimer's or dementia | 23% | |
| Chronic kidney disease | 21% | |
| Cancer | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, onabotulinumtoxina, 1 unit J0585 | Office | 23 | 9,700 | $48,222 |
| Injection, rimabotulinumtoxinb, 100 units J0587 | Office | 22 | 3,052 | $31,099 |
| Injection, incobotulinumtoxin a, 1 unit J0588 | Office | 28 | 6,280 | $25,802 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
95 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurology in New York
Related records
Neurology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Neurology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.